Biospecifics Technologies Corp. (BSTC)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas L. Wegman
Employees:
5
35 WILBUR ST, LYNBROOK, NY 11563
5165937000

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

BioSpecifics Technologies Corp. operates as a biopharmaceutical company, which engages in development of an injectable collagenase for multiple indications. Its product includes XIAFLEX, is an injectable collagenase enzyme, which is used for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Data derived from most recent annual or quarterly report
Market Cap 650.696 Million Shares Outstanding7.35 Million Avg 30-day Volume 109.378 Thousand
P/E Ratio22.425 Dividend Yield0.0 EPS1.36
Price to Revenue10.636 Debt to Equity0.0 EBITDA20.576 Million
Price to Book Value2.8762 Operating Margin55.884 Enterprise Value268.146 Million
Current Ratio66.229 EPS Growth-0.25 Quick Ratio65.089
1 Yr BETA 0.7652 52-week High/Low 89.15 / 42.0 Profit Margin47.4294
Operating Cash Flow Growth20.9801 Altman Z-Score122.1615 Free Cash Flow to Firm 20.434 Million
View SEC Filings from BSTC instead.

View recent insider trading info

Biospecifics Technologies Corp. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding BSTC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BSTC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2020-12-08 by Endo International plc
  • 4: filed on 2020-12-02 by CHAO JENNIFER M
  • 4: filed on 2020-12-02 by WEGMAN TOBY
  • 4: filed on 2020-12-02 by FISHMAN COREY N.
  • 4: filed on 2020-12-02 by WEGMAN MARK N
  • 4: filed on 2020-12-02 by SCHAMROTH MICHAEL
  • 4: filed on 2020-12-02 by TRUITT JOSEPH
  • 4: filed on 2020-12-02 by GITMAN PAUL
  • 4: filed on 2020-12-02 by HUTCHISON PATRICK
  • 4: filed on 2020-12-02 by SHERMAN MICHAEL A.

    • Events (8k)

  • 8-K: filed on 2020-12-02:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-09-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-20:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GITMAN PAUL

    • Director
    		 No longer subject to file 2020-12-02 0

    SCHAMROTH MICHAEL

    • Director
    		 No longer subject to file 2020-12-02 0

    WEGMAN TOBY

    • Director
    • 10% Owner
    		 No longer subject to file 2020-12-02 0

    WEGMAN MARK N

    • Director
    • 10% Owner
    		 No longer subject to file 2020-12-02 0

    TRUITT JOSEPH CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 No longer subject to file 2020-12-02 0

    SHERMAN MICHAEL A.

    • Director
    		 No longer subject to file 2020-12-02 0

    FISHMAN COREY N.

    • Director
    		 No longer subject to file 2020-12-02 0

    ENDO INTERNATIONAL PLC

    • 10% Owner
    		 100 2020-12-02 0

    CHAO JENNIFER M

    • Director
    		 No longer subject to file 2020-12-02 0

    HUTCHISON PATRICK CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-12-02 0

    BUCHI J KEVIN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2019-10-23 0

    CALDWELL PATRICK M PRINCIPAL FINANCIAL OFFICER

    • Officer
    		 1,000 2019-10-01 0

    MATTILA JYRKI

    • Director
    		 376 2019-05-22 0

    LAW RONALD EDWARD SVP BUSINESS DEVELOPMENT

    • Officer
    		 0 2019-01-23 0

    WEGMAN THOMAS PRESIDENT

    • Officer
    • Director
    • 10% Owner
    		 1,238,800 2018-08-16 0

    ESTATE OF EDWIN H. WEGMAN

    • 10% Owner
    		 947,473 2016-05-18 0

    VOGEL JEFFREY KENNETH

    • 5% OWNER
    		 508,656 2015-10-28 0

    LINK MAX

    • Director
    		 0 2014-08-04 0

    MORGAN HENRY

    • Director
    		 32,193 2014-06-06 0

    GOULD GEORGE M

    • Director
    		 0 2013-09-17 0

    GELLER MATTHEW

    • Director
    		 0 2011-06-06 0

    RA CAPITAL MANAGEMENT, LLC

    KOLCHINSKY PETER

    RA CAPITAL HEALTHCARE FUND LP

    • 10% Owner
    		 No longer subject to file 2010-02-26 0

    RA CAPITAL MANAGEMENT, LLC

    KOLCHINSKY PETER

    RA CAPITAL HEALTHCARE FUND LP

    RA CAPITAL HEALTHCARE FUND II, L.P.

    • 10% Owner
    		 841,603 2009-04-24 0

    RA CAPITAL MANAGEMENT, LLC

    ALDRICH RICHARD

    KOLCHINSKY PETER

    RA CAPITAL HEALTHCARE FUND LP

    RA CAPITAL HEALTHCARE FUND II, L.P.

    • 10% Owner
    		 742,196 2008-11-17 0

    DOBROFF LAWRENCE CHIEF FINANCIAL OFFICER

    • Officer
    		 25,000 2006-01-23 0

    WEGMAN EDWIN CHAIRMAN AND CEO

    • Officer
    • Director
    • 10% Owner
    		 139,000 2006-01-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments